News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AOL.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bank of America Corp DE reduced its stake in iRhythm Technologies by 41.7% in Q1, selling over 309,000 shares but still holding shares worth $51 million. Despite this reduction, iRhythm reported strong Q1 results with revenue up 20.1% year-over-year and earnings exceeding analyst expectations. …
The Top 5 Analyst Questions From iRhythm's Q2 Earnings Call iRhythm's second quarter results were met with a strong positive market reaction, reflecting the company's ability to deliver both robust revenue growth and significant margin improvement. Management attributed this performance to sustained demand for …
Analysts have given iRhythm Technologies (NASDAQ:IRTC) an average recommendation of "Moderate Buy," with a consensus price target of $179.93. The company recently reported strong quarterly earnings, beating expectations with an EPS of $0.58 and revenue of $224.17 million, a 20.1% year-over-year increase. Institutional investors, …
[Doctor and patient in conversation, looking at digital tablet] Solskin * iRhythm (IRTC [https://seekingalpha.com/symbol/IRTC]) ticked lower by 2% amid comments from Spruce Point Research. * iRhythm (IRTC [https://seekingalpha.com/symbol/IRTC]) didn't immediately respond to Seeking Alpha's email request for comment. * Spruce Point first issued a …
Quantinno Capital Management LP significantly increased its stake in iRhythm Technologies (NASDAQ:IRTC) by 1,172.8% in the first quarter, now owning 18,621 shares valued at approximately $2.2 million. The company reported strong financial results, with quarterly revenue up 20.1% year over year to $224.17 million …
This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), detailing institutional trading strategies based on AI models. It identifies strong near- and mid-term sentiment but a weak long-term outlook, with key support and resistance levels. The analysis also highlights a significant …
Why iRhythm (IRTC) Stock Is Trading Up Today What Happened? Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong second-quarter financial results that surpassed expectations and raised its full-year guidance. The cardiac monitoring company …
Truist Financial has increased its price target for iRhythm Technologies (NASDAQ:IRTC) from $160 to $168, maintaining a "buy" rating and indicating a potential upside of 34.59%. This positive outlook aligns with a "Moderate Buy" consensus rating from MarketBeat analysts, despite some recent target reductions …
Oppenheimer expects iRhythm Technologies to benefit from its acquisition of VitalConnect, which will add a significant product to its portfolio and is expected to be immediately accretive to margins. The firm reiterates an Outperform rating and a $170 price target for iRhythm, citing potential …
iRhythm Holdings, Inc. IRTC reported adjusted earnings per share of 58 cents in the second quarter of 2026, against an adjusted loss per share of 32 cents a year ago. The figure beat the Zacks Consensus Estimate by 5900%. GAAP loss per share for …
Shares of iRhythm Technologies (IRTC) fell after an analyst significantly cut their price target on the stock, despite the company reporting strong quarterly earnings and raising its full-year revenue guidance. Truist lowered its price target to $18 from $160, even while maintaining a "Buy" …
IRhythm announced its acquisition of VitalConnect for $287.5 million to expand its mobile cardiac telemetry (MCT) capabilities. This acquisition is expected to unlock access to an additional $500 million market opportunity within the $1 billion cardiac monitoring market. While IRhythm remains committed to securing …
IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 20.1% year on year to $224.2 million. The company expects the full year's …
Kuehn Law, PLLC is investigating iRhythm Technologies, Inc. (IRTC) for potential breaches of fiduciary duties by its officers and directors. The investigation stems from allegations that the company misrepresented the Zio AT monitor's capabilities and market penetration, leading to artificially inflated stock prices. The …
iRhythm Technologies (IRTC) recently settled a patent dispute for $50 million and announced strong Q2 2026 results, including a 20.1% revenue increase and improved margins. The company also secured FDA clearance for a new algorithm and plans to acquire Vital Connect for $287.5 million …
Wall Street Zen has downgraded iRhythm Technologies (NASDAQ:IRTC) to a "Hold" rating from "Buy," despite the company's strong Q2 results and a broader analyst consensus of "Moderate Buy." iRhythm reported earnings of $0.58 per share against an expected loss and saw revenue increase by …
iRhythm Technologies reported its seventh consecutive quarter of over 20% revenue growth, driven by strong demand across cardiology, primary care, and international markets. The company announced the acquisition of VitalConnect to expand into new cardiac monitoring modalities and raised its full-year 2026 revenue guidance …
In early August 2026, iRhythm Holdings reported second-quarter 2026 results showing sales rising to US$224.17 million and net loss narrowing to US$0.381 million, while also increasing its full-year 2026 revenue guidance to US$880 million–US$890 million and announcing a proposed US$45.00 million securities class action …
iRhythm has announced the acquisition of VitalConnect for $287.5 million, a move aimed at expanding its cardiac monitoring platform across various healthcare settings. The deal, expected to close by the end of 2026, combines cash and iRhythm common stock. This acquisition is anticipated to …
This article provides current stock information for iRhythm Technologies Inc (IRTC), including its stock price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the TradingKey platform for investors.
Truist Securities has increased its price target for iRhythm Technologies (IRTC) to $168 from $160, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance by the investment bank.
Needham has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $192 from $255, while maintaining a Buy rating. The adjustment comes despite iRhythm exceeding Q2 2026 revenue expectations and raising its full-year guidance, partly due to the acquisition of VitalConnect which is expected …
iRhythm Technologies, Inc. (IRTC) reported strong Q2 revenue growth of 20.1% year-over-year, leading to raised full-year guidance and a strategic acquisition to expand its cardiac monitoring capabilities. Despite being unprofitable, the company is considered 22.6% undervalued based on its GF Value™ and shows strong …
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points iRhythm Holdings Inc (NASDAQ:IRTC) delivered its seventh consecutive quarter of revenue growth above 20%, with …
iRhythm Technologies (IRTC) reported strong Q2 2026 results, exceeding revenue forecasts and demonstrating significant margin expansion, leading to a stock increase. The company announced the acquisition of VitalConnect, which is expected to expand its cardiac monitoring offerings and accelerate its entry into new markets …
iRhythm Technologies (IRTC) has announced its revenue expectations for 2026, forecasting a range of $880 million to $890 million. This projection is in line with FactSet's estimated revenue of $881.1 million for the same period. The company also reported its Q2 2026 earnings, with …
iRhythm (NASDAQ:IRTC) Beats Q2 CY2026 Sales Expectations Medical technology company iRhythm Technologies (NASDAQ:IRTC) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 20.1% year on year to $224.2 million. The company expects the full year's revenue to be around $885 million, close …
iRhythm Holdings, Inc. announced its definitive agreement to acquire VitalConnect for approximately $287.5 million, comprising cash and iRhythm common stock. This acquisition is expected to broaden iRhythm's cardiac monitoring platform by adding mobile cardiac telemetry and multi-vitals monitoring capabilities, expanding its addressable market across …
Search by ticker symbol or company name and select a result to open its chart.